Tissue plasminogen activator (tPA) antigen in plasma: Correlation with different tPA/inhibitor complexes

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 58, Issue 6, 1998, Pages 475-484

  Nordenhem, A ^a   Wiman, B ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antiplasmin; C1 inhibitor; Fibrinolysis; PAI 1; tPA

Indexed keywords

ANTIPLASMIN; PROTEINASE; TISSUE PLASMINOGEN ACTIVATOR;

ANTIGEN SPECIFICITY; ARTICLE; BLOOD SAMPLING; CLINICAL CHEMISTRY; COMPLEX FORMATION; DEEP VEIN THROMBOSIS; ENZYME INACTIVATION; ENZYME INHIBITOR COMPLEX; FIBRINOLYSIS; HUMAN; HUMAN CELL; PREDICTION; PRIORITY JOURNAL;

ADULT; ANTIPLASMIN; COMPLEMENT C1 INACTIVATOR PROTEINS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0031790154     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365519850186274     Document Type: Article

References (24)

1. Wiman B. Plasminogen activator inhibitor 1 in thrombotic disease. Curr Opin Hematol 1996; 3: 372-8.
2. Hamsten A, de Faire U, Walldius G, Dahlén G, Szamosi A, Landou C, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
3. Cortellaro M, Cofrancesco E, Boscheti C, Mussoni L, Donati MB, Cardillo M, et al., for the PLAT Group. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in artherosclerotic patients - a case-control study. Arterioscler Thromb 1993; 13: 1412-17.
4. Held C, Hjelmdahl P, Rehnqvist N, Wallén H, Björkander I, Eriksson S, et al. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Circulation 1997; 95: 2380-6.
5. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 1993; 88: 2030-4.
6. Ridker PM, Vaughan PE, Stampfer MJ, Manson JE, Hennehens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-8.
7. Schulman S, Wiman B. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Thromb Haemost 1996; 75: 607-11.
8. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW, for the European concerted action on thrombosis and disabilities angina pectoris study group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 322: 635-41.
9. Thorsen S, Philips M. Isolation of tissue-type plasminogen activator-inhibitor complexes from human plasma. Biochim Biophys Acta 1984; 802: 111-18.
10. Booth NA, Walker E, Maughan R, Bennet B. Plasminogen activator in normal subjects after exercise and venous occlusion: t-PA circulates as complexes with C1-inhibitor and PAI-1. Blood 1987; 69: 1600-4.
11. Chandler WL, Levy WC, Stratton JR. The circulatory regulation of TPA and UPA secretion, clearance, and inhibition during exercise and during the infusion of isoproterenol and phenylephrine. Circulation 1995; 92: 2984-94.
12. Huisman LGM, van Griensven JMT, Kluft C. On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma. Thromb Haemost 1995; 73: 466-71.
13. Korninger C, Collen D. Neutralisation of human extrinsic (tissue-type) plasminogen activator in human plasma: no evidence for specific inhibitor. Thromb Haemost 1981; 46: 662-5.
14. Nilsson TK. Analysis of factors affecting tissue plasminogen activity and antigen concentration before and after venous occlusion in 123 patients. Clin Chem Enzymol Comm 1989; 1: 335-41.
15. Wiman B, Hamsten A. Impaired fibrinolysis and risk of thromboembolism. Progr Cardiovasc Dis 1991; 34: 179-92.
16. Wiman B. Affinity-chromatographic purification of human α-antiplasmin. Biochem J 1981; 191: 229-32.
17. Nilsson T, Wiman B. Purification and characterization of human C1-esterase inhibitor. Biochim Biophys Acta 1982; 705: 271-6.
18. Lindahl T, Wiman B. Purification of high and low molecular weight plasminogen activator inhibitor 1 from fibrosarcoma cell-line HT 1080 conditioned medium. Biochim Biophys Acta 1989; 994: 253-7.
19. Lindahl T, Sigurdardottir O, Wiman B. Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost 1989; 62: 748-51.
20. Tijssen P, Kurstak E. Highly efficient and simple methods for preparation of peroxidase and active peroxidase-antibody conjugates for enzyme immunoassays. Analyt Biochem 1984; 136: 451-7.
21. Chmielewska J, Rånby M, Wiman B. Kinetics of the inhibition of plasminogen activators by the plasminogen activator inhibitor. Evidence for second-site interactions. Biochem J 1988; 251: 327-33.
22. Laemmli UK. Cleavage of structural proteins during the assembly of the head bacteriophage T4. Nature 1970; 227: 680-5.
23. Urdén G, Hamsten A, Wiman B. Comparison of plasminogen activator inhibitor activity and antigen in plasma samples. Clin Chim Acta 1987; 169: 189-96.
24. Rånby M, Nguyen G, Scarabin PY, Samama M. Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes. Thromb Haemost 1989; 61: 409-14.